Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMV1J21)

Drug Name
AAV-hTERT Drug Info
Indication
Disease Entry ICD 11 Status REF
Aging MG2A Phase 1 [1]
Alzheimer disease 8A20 Phase 1 [1]
Critical limb ischemia BD4Y Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMV1J21

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Telomerase reverse transcriptase (TERT) TTUJFD0 TERT_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Telomerase reverse transcriptase (TERT) DTT TERT 1.848 3.217 2.485 3.406
Telomerase reverse transcriptase (TERT) DTT TERT 1.848 3.217 2.485 3.406
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Aging
ICD Disease Classification MG2A
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Telomerase reverse transcriptase (TERT) DTT TERT 8.59E-10 -0.08 -0.33
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04133649) Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for the Treatment of Aging: AAV- hTERT. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04110964) Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for Critical Limb Ischemia: AAV- hTERT. U.S.National Institutes of Health.